Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Jayk Bernal, Angélica; Maria Gomes da Silva, Monica; Badibanga Musungaie, Dany; A. Kovalchuk, E.; Gonzalez, Antonio; Delos Reyes, Virginia; Martín‐Quirós, Alejandro; Caraco, Yoseph; Williams‐Diaz, Angela; Brown, Michelle; Du, Jiejun; Pedley, Alison; Assaid, Christopher; Strizki, Julie; A. Grobler, Jay; Shamsuddin, Hala; Tipping, Robert; Wan, Hong; Paschke, Amanda; R. Butterton, Joan; G. Johnson, Matthew; De Anda, Carisa

doi:10.1056/nejmoa2116044

Public

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Published in New England Journal of Medicine • Dec 16, 2021

Authors:

Angélica Jayk Bernal

Monica Maria Gomes da Silva

Dany Badibanga Musungaie

Abstract

BACKGROUND: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We conducted a phase 3, double-blind...

Subject

Coronavirus disease 2019 (COVID-19)

Prodrug

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!